CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 179 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02455375
NCT02455375N/ACompleted

Puumala Hantavirus Infection in France: Evaluation of Commercial Assays for the Detection of Antibodies Against This Virus and the Use of Urine Samples for the Molecular Detection of This Infection

Centre Hospitalier de Charleville-Mézières·observational·Posted May 27, 2015·Updated Aug 25, 2023

In Brief

An observational study for Nephropathia Epidemica and Hemorrhagic Fever With Renal Syndrome. Completed, enrolled 179 participants across 10 sites.

Detailed Summary

Routine Puumala virus (PUUV) infection diagnosis is performed using serological commercial kits of which performances have not been established in real life, which use recombinant protein from strains from Central or North Europe. Molecular diagnostic of these infection is not the rule. Consequently the objectives of the project are to evaluate the performances of the serological commercial assays in real life in France and to assess the use of urine versus plasma for the molecular diagnostic of this infection.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesFrance
CollaboratorsInstitut Pasteur

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 27, 2015
Enrollment StartJul 1, 2015
Primary CompletionNov 30, 2021
TodayJul 2, 2026
Enrollment to primary: 6.4 yearsPosted 11.1 years ago